ISSCR News
The ISSCR Shared Comments on Hong Kong's Draft Guidance for Cell and Tissue Products
The ISSCR recently offered comments on the draft Guidance for Cell and Tissue Products (those not classified as Advanced Therapy Products) with Assistant Director Frank Chan, Drug Office, Department of Health, Hong Kong.
The ISSCR Leads Coalition Letter to President-elect Biden on Human Fetal Tissue Research
The ISSCR and a coalition of 98 scientific, medical, and patient communities dedicated to advancing medical knowledge and improving human health urged President-elect Biden to swiftly rescind the human fetal tissue (HFT) research restrictions and policy changes that the Department of Health and Human Services made in 2019. Among other key points, the letter stated that these changes have halted all intramural HFT research and obstructed new extramural research involving HFT. Scientists and ethicists have repeatedly reviewed the use of HFT in research and have consistently concluded that HFT is an essential resource for biomedical research. HFT has led to many scientific and medical advances that have saved millions of lives. It remains critical for the development of new treatments for a wide range of serious diseases, including COVID-19.
The ISSCR’s VISION2030 Gathers Global Leaders in Stem Cell Research and Regenerative Medicine to Chart the Next Decade of Breakthroughs
Biotech business innovators and scientific trailblazers converge for a must attend future-forward event 7-8 January 2021
Skokie, IL – The ISSCR’s VISION2030: A Forecast for the Field is bringing together biotech CEOs who have successfully transformed scientific breakthroughs into thriving businesses that are improving human health. Join us for in-depth executive interviews that explore the next decade for the field on 7-8 January 2021. The event comes at a pivotal moment in regenerative medicine and stem cell science as discovery, translation, and investment intersect. Register and see the full program.
The ISSCR Shared Comments on Hong Kong’s Draft Guidance for Cell and Tissue Products
The ISSCR condemns the premature commercialization of unproven cell therapies, which has resulted in patients being blinded, paralyzed, and infected with dangerous pathogens. In many countries, unscrupulous businesses marketing these unproven cell therapies have abused ambiguous definitions for substantial/minimal manipulation and homologous use to claim they are not subject to oversight. Regulators around the world need to adopt harmonized product definitions to protect public health and to prevent the premature commercialization of stem cell-based products.
The ISSCR Signs Ad Hoc Group for Medical Research Coalition Letter on NIH to President-elect Biden
The ISSCR joined with the Ad Hoc Group for Medical Research and 349 member organizations representing patients, clinicians, scientists, educators, academic institutions, research organizations, and industry, in a letter thanking President-elect Joseph R. Biden, Jr. for his steadfast support for science. The letter states, "As the oldest coalition advocating for the federal investment in the National Institutes of Health (NIH) and biomedical, bioengineering, behavioral, and social science research, we are grateful that you support increased and sustainable funding growth for the NIH as part of $300 billion in new research and development investments in your Build Back Better plan."
Receive ISSCR Press Releases
Sign up be a part of ISSCR’s media list. Media Contact: Kym Kilbourne, Director of Media and Strategic Communications
Subscribe to ISSCR News.
Each month, ISSCR delivers scientific, policy, and community to your inbox .